CDMOP - CDMOP STOCK NEWS

Avid Bioservices (NASDAQ: CDMO) has filed an investor presentation regarding its pending transaction with GHO Capital Partners and Ampersand Capital Partners. The deal offers stockholders a significant premium, including a 63.8% premium to the June 4, 2024 closing price. The transaction resulted from a robust process where the Board rejected two initial proposals before conducting a broader search involving 24 potential parties, with seven conducting due diligence.

The deal's value exceeds trading multiples of comparable companies and represents a 24.9% premium to the company's discounted cash flow analysis. The Board highlights that while Avid has made strategic investments, additional funding is needed for growth potential. The company's five-year growth prospects were noted to be below previous guidance and analyst consensus.

A Special Meeting to vote on the transaction is scheduled for January 30, 2025, with stockholders of record as of December 11, 2024, eligible to vote. The Board unanimously recommends voting 'FOR' the transaction.

Avid Bioservices (NASDAQ: CDMO) announced the expiration of the Hart-Scott-Rodino waiting period for its pending acquisition by GHO Capital Partners LLP and Ampersand Capital Partners. This marks a significant milestone toward completing the transaction, which is expected to close in the first quarter of 2025. The deal remains subject to stockholder approval and other customary closing conditions. Nick Green, Avid's president and CEO, emphasized that the transaction will deliver significant, immediate, and certain value to stockholders, encouraging them to vote in favor of the deal. Moelis & Company serves as exclusive financial advisor, with Cooley LLP as legal counsel to Avid.

Avid Bioservices (NASDAQ: CDMO) has initiated mailing definitive proxy materials to stockholders regarding its pending transaction with GHO Capital Partners and Ampersand Capital Partners. The deal offers $12.50 per share in cash, representing a $1.1 billion enterprise value and a 13.8% premium to the last trading price before announcement.

The Special Meeting to vote on the transaction is scheduled for January 30, 2025. The Board unanimously recommends stockholders vote 'FOR' the transaction, highlighting three key benefits: immediate cash value, a robust value-maximizing process, and de-risking of the company's standalone future. The deal followed a comprehensive process involving outreach to 24 potential buyers, resulting in a 19% price improvement from the initial unsolicited offer.

Avid Bioservices (NASDAQ: CDMO) reported financial results for Q2 FY2025 ended October 31, 2024. Revenue increased 32% to $33.5 million, while backlog grew 11% to $220 million. Despite revenue growth, the company recorded a gross loss of $2.0 million and a net loss of $17.4 million ($0.27 per share).

The company announced its acquisition by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at $1.1 billion. Shareholders will receive $12.50 per share, representing a 13.8% premium to the closing price on November 6, 2024. The transaction is expected to close in Q1 2025, after which Avid will become private.

Avid Bioservices (NASDAQ: CDMO) has announced a definitive merger agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at $1.1 billion. Shareholders will receive $12.50 per share, representing a 13.8% premium to Avid's closing price on November 6, 2024. The transaction equates to a 6.3x multiple to consensus FY2025E revenue. The deal, unanimously approved by Avid's Board, is expected to close in Q1 2025, subject to stockholder and regulatory approvals. Post-acquisition, Avid will become private while maintaining its name and brand.

Avid Bioservices (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization, has announced its participation in the upcoming Craig-Hallum Bioprocessing Conference. The virtual event is scheduled for September 19, 2024.

Key highlights:

• President and CEO Nick Green and VP of Process Development Pramthesh Patel, Ph.D., will be featured speakers
• The fireside chat is set for 2:45 p.m. Eastern on the conference day
• A webcast replay will be available on Avid's investor website after the event

This participation underscores Avid Bioservices' commitment to engaging with industry stakeholders and showcasing its expertise in biologics manufacturing and development services.

Avid Bioservices (NASDAQ: CDMO) reported financial results for Q1 FY2025 ended July 31, 2024. Key highlights include:

- Revenue of $40.2 million, up 6% year-over-year
- Net new business signings of $66 million
- Backlog increased to $219 million, up 16% from last year
- Gross profit of $5.7 million (14% margin)
- Net loss of $5.5 million or $0.09 per share
- Cash and equivalents of $33.4 million

The company maintained its FY2025 revenue guidance of $160-$168 million. Avid's CEO Nick Green highlighted strong momentum, improved margins, and diverse new business signings, including early-phase programs and late-stage projects advancing toward commercialization.

Avid Bioservices (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization, has announced it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close. The company will also host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) on the same day. During the webcast, Avid's senior management will discuss the financial results and review recent corporate developments. Investors and interested parties can access the live or archived webcast through the company's investor relations website.

Avid Bioservices (NASDAQ: CDMO) reported fourth quarter revenue of $43 million, the highest in the company's history, and full-year fiscal 2024 revenue of $139.9 million, a 6% decrease from the previous year. Despite a strong quarter, the full year was impacted by fewer manufacturing runs and changes in estimated variable consideration. The company signed $30 million in new business, resulting in a backlog of $193 million. For fiscal 2025, Avid projects revenue between $160 million and $168 million. Gross profit for Q4 was $5.5 million (13% margin), down from $8.4 million (21% margin) in Q4 2023. Full-year gross profit was $7.3 million (5% margin), down from $31.5 million (21% margin) last year. The net loss for Q4 was $123.1 million or $1.94 per share, primarily due to a $118.5 million income tax expense. The net loss for the full year was $140.8 million or $2.23 per share, compared to net income of $0.3 million last year. Cash and cash equivalents stood at $38.1 million as of April 30, 2024. New facilities are fully operational, increasing the annual revenue-generating capacity to over $400 million.